Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 34.e9-34.e18

  Hudson, M'Liss A ^a,b   Luo, Suhong ^b   Chrusciel, Timothy ^b   Yan, Yan ^c   Grubb, Robert L ^a,b   Carson, Kenneth ^a   Scherrer, Jeffrey F ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Washington University in St Louis School of Medicine   (United States)

Author keywords

Access to care; African American; Cancer detection; Cancer screening; Prostate cancer; Prostate specific antigen; Racial disparities

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SCREENING; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RACE DIFFERENCE; VETERAN; AFRICAN AMERICAN; BIOPSY; BLOOD; CAUCASIAN; COHORT ANALYSIS; EARLY CANCER DIAGNOSIS; ETHNOLOGY; GOVERNMENT; HEALTH CARE DISPARITY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGED; BIOPSY; COHORT STUDIES; EARLY DETECTION OF CANCER; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTHCARE DISPARITIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS;

EID: 84890802469     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.01.003     Document Type: Article

References (34)

1. Society AC. Cancer Facts & Figures for African Americans 2011-2012. 1-32. 〈〉; 2012 [accessed 31.01.12]. http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFiguresforAfricanAmericans/cancer-facts-figures-af-am-2011-2012.
2. Nelson A. Unequal treatment: confronting racial and ethnic disparities in health care. J Natl Med Assoc 2002, 94(8):666-668.
3. French D.B., Jones L.A. Minority issues in prostate disease. Medi Clin North Am 2005, 89(4):805-816.
4. Saha S, Freeman M, Toure J, Tippens KM, Weeks C. Racial and ethnic disparities in the VA Healthcare System: a systematic review. Washington (DC): Department of Veterans Affairs (US); 2007.
5. Banez L.L., Terris M.K., Aronson W.J., et al. Race and time from diagnosis to radical prostatectomy: does equal access mean equal timely access to the operating room?-Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev 2009, 18(4):1208-1212.
6. Jha A.K., Perlin J.B., Kizer K.W., Dudley R.A. Effect of the transformation of the Veterans Affairs Health Care System on the quality of care. N Engl J Med 2003, 348(22):2218-2227.
7. Amling C.L., Riffenburgh R.H., Sun L., et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004, 22(3):439-445.
8. Hamilton R.J., Aronson W.J., Presti J.C., et al. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer 2007, 110(10):2202-2209.
9. Andriole G.L., Crawford E.D., Grubb R.L., et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012, 104(2):125-132.
10. Schroder F.H., Hugosson J., Roobol M.J., et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012, 366(11):981-990.
11. Service HSRaDVA informatics and computing infrastructure. 〈〉 [accessed 16.05.11]. http://www.hsrd.research.va.gov/for_researchers/vinci.
12. VIReC Race Data Quality update, June 2008; 2008.
13. ICD-9. International classification of diseases. Geneva: World Health Organization; 1979.
14. Terminology Pcp. CPT 2009. Chicago: American Medical Association; 2008.
15. Scherrer J.F., Chrusciel T., Zeringue A., et al. Anxiety disorders increase risk for incident myocardial infarction in depressed and nondepressed Veterans Administration patients. Am Heart J 2010, 159(5):772-779.
16. Romano P.S., Roos LL, Jollis J.G. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993, 46:1075-1079.
17. Crawford E.D., Grubb R., Black A., et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol 2011, 29(4):355-361.
18. Hosmer-Lemoshow F. SAS/STAT user's guide 1999, SAS Institute Inc, Cary, NC.
19. Andriole G.L., Levin D.L., Crawford E.D., et al. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005, 97(6):433-438.
20. Vollmer R.T. Race and the linkage between serum prostate-specific antigen and prostate cancer: a study of American veterans. Am J Clin Pathol 2004, 122(3):338-344.
21. DeAntoni E.P., Crawford E.D., Oesterling J.E., et al. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology 1996, 48(2):234-239.
22. Grubb R.L., Pinsky P.F., Greenlee R.T., et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 2008, 102(11):1524-1530.
23. Zeliadt S.B., Hoffman R.M., Etzioni R., Ginger V.A., Lin D.W. What happens after an elevated PSA test: the experience of 13,591 veterans. J Gen Intern Med 2010, 25(11):1205-1210.
24. Ross L.E., Berkowitz Z., Ekwueme D.U. Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 2008, 17(3):636-644.
25. Garbis S.D., Tyritzis S.I., Roumeliotis T., et al. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 2008, 7(8):3146-3158.
26. American Urological Association Prostate-specific Antigen Best Practices Policy updated 2009; 2009.
27. American Cancer Society Prostate Cancer Screening Guidelines; 2010.
28. Drazer MWea. Impact of US Preventative Task Force recommendation on screening for prostate cancer in men aged 75 or older. Presented at the 2012 Genitourinary Cancers Symposium in San Francisco; 2012.
29. Talcott J.A., Spain P., Clark J.A., et al. Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experience. Cancer 2007, 109(8):1599-1606.
30. Prevention CfDCa. FASTSTATS leading causes of death. 〈〉; 2011 [accessed 11.11.11]. http://www.cdc.gov/nchs/fastats/lcod.htm.
31. Walter L.C., BD, Lindquist K., Konety B.R. PSA screening among elderly men with limited life expectancies. J Am Med Assoc 2006, 296(19):2336-2342.
32. Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology 2000;14(2): 267-72, 77-8, 80 passim.
33. Schroder F.H., Raaijmakers R., Postma R., van der Kwast T.H., Roobol M.J. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. J Urol 2005, 174(2):489-494. [discussion 93-4].
34. Moyer V.A. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012, 157(2):120-134.